High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23) - PubMed (original) (raw)

. 2011 Jan 20;117(3):928-35.

doi: 10.1182/blood-2010-05-286138. Epub 2010 Nov 2.

Eva A Coenen, Brian V Balgobind, Jan Stary, Andre Baruchel, Valerie de Haas, Eveline S J M de Bont, Dirk Reinhardt, Gertjan J L Kaspers, Jacqueline Cloos, Astrid A Danen-van Oorschot, Monique L den Boer, Rolf Marschalek, Claus Meyer, Rob Pieters, C Michel Zwaan, Marry M van den Heuvel-Eibrink

Affiliations

Free article

High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)

Jenny E Kuipers et al. Blood. 2011.

Free article

Abstract

Pediatric mixed-lineage leukemia (MLL)-rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9;11)(p22;q23) patients with 42 other MLL-rearranged AML patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9;11)(p22;q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4 expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)-M5 versus other FAB-types (P = .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4 by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4 expression (5-year overall survival 0.70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources